Abstract
The force of infection, or the rate at which susceptible individuals become infected, is an important public health measure for assessing the extent of outbreaks and the impact of control programs. Here we present methods for estimating force of infection from serological surveys of infections which produce lasting immunity, taking into account imperfections in the test used, and uncertainty in such imperfections. The methods cover both single serological surveys, in which age is a proxy for time at risk, and repeat surveys in the same people, in which the force of infection is estimated more directly. Fixed values can be used for the sensitivity and specificity of the tests, or existing methods for belief elicitation can be used to include uncertainty in these values. The latter may be applicable, for example, when the specificity of a test depends on co-circulating pathogens, which may not have been well characterized in the setting of interest. We illustrate the methods using data from two published serological studies of dengue.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Neal Alexander receives salary support from a) grant number MR/R010161/1 from the United Kingdom (UK) Medical Research Council and UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the EDCTP2 programme supported by the European Union, and b) an award from FAPESP (2018/14389-0) and the UK Medical Research Council (MR/S0195/1) for the Brazil-UK Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology (CADDE). Mabel Carabali holds a Canadian Institutes of Health Research Banting Best Doctoral Award fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used have either been previously published or are covered by obtained ethical approval from the Ethics Committee of the University of Antioquia (Colombia), Municipal Health Office (Secretaria de Salud de Medellin, colombia) and the Institutional Review Board of the International Vaccine Institute (IVI, Republic of Korea).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Abbreviations
- COVID-19
- coronavirus disease 2019
- DAG
- directed acyclic graph
- ELISA
- enzyme-linked immunosorbent assay
- IgG
- immunoglobulin G
- MCMC
- Markov chain Monte Carlo
- NPV
- negative predictive value
- PPV
- positive predictive value
- Se
- sensitivity
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- Sp
- specificity
